Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

Agreement gives Ipsen global rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational

Related Keywords

Paris ,France General ,France ,Saclay ,Taiwan ,Shanghai ,China ,Schattenberg ,Sachsen ,Germany ,United States ,Hong Kong ,Cambridge ,Cambridgeshire ,United Kingdom ,Macau ,American ,Fanny Allaire ,Pascal Prigent ,Jess Smith ,David Loew ,Ipsen Euronext ,Global Communications ,European Commission ,Uncertainties Of The Company ,Drug Administration ,Terns Pharmaceuticals ,Nasdaq ,Exchange Commission ,Head Of Global Communications ,European Medicines Agency ,Euronext ,Stephanie Boyer ,Business Development ,Primary Biliary Cholangitis ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Chief Executive Officer ,Biliary Cholangitis ,Breakthrough Therapy ,Rare Disease ,Consumer Healthcare ,Total Sales ,Sponsored Leveli American Depositary Receipt ,Chronic Liver Failure ,Nasdaq Global Select Market ,French Autorit ,Des March ,Private Securities Litigation Reform Act ,Registration Document ,Transplantation Hepatology ,Investor Relations ,Relations Manager ,Communications Director ,Boyer Press ,Lipsen ,Genfit ,Winter ,Into ,Exclusive ,Icensing ,Agreement ,Elafibranor ,Hase ,Sset ,Revaluated ,Primary ,Miliary ,Cholangitis ,Art ,Song ,Term ,Lobal ,Partnership ,